Related Experiment Video

Updated: Dec 30, 2025

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

644

Can advanced glycation end-products and their receptors be affected by weight loss? A systematic review

Juliana F Tavares1, Priscila V M Ribeiro1, Olívia G L Coelho1

  • 1Departamento de Nutrição e Saúde, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.

Obesity Reviews : an Official Journal of the International Association for the Study of Obesity
|January 18, 2020
PubMed

Insights

Weight loss interventions, including diets and bariatric surgery, can reduce advanced glycation end products (AGEs). However, their impact on AGEs receptors requires further study.

Area of Science:

  • Metabolism and Endocrinology
  • Biochemistry
  • Cardiovascular Disease Research

Background:

  • Advanced glycation end products (AGEs) are linked to chronic disease pathogenesis.
  • Reducing AGEs and preventing cardiometabolic complications is a public health priority.
  • Weight management interventions show promise in lowering serum AGE concentrations.

Purpose of the Study:

  • To systematically review studies on the effects of weight loss on serum AGEs and their receptors in adults with excess body weight.
  • To analyze the impact of energy-restricted diets and bariatric surgery on AGEs and soluble receptor for advanced glycation end products (sRAGE).

Main Methods:

  • Systematic literature search of MEDLINE, Cochrane, Scopus, and Lilacs databases.
  • Inclusion of three studies on AGEs response to energy-restricted diets.
  • Inclusion of six studies assessing sRAGE as a primary outcome.

Main Results:

  • Energy-restricted diets and bariatric surgery were found to reduce serum AGE concentrations.
  • Conflicting results were observed regarding the effects of these interventions on endogenous secretory RAGE (esRAGE) and sRAGE concentrations.
  • Observed effects may be linked to dietary changes and reduced endogenous AGE formation.

Conclusions:

  • Weight loss interventions effectively lower serum AGE concentrations.
  • The impact of weight loss on AGEs receptors (sRAGE and esRAGE) requires further investigation.
  • Future research should explore the mechanisms underlying these effects.
Keywords:
advanced glycation end productbariatric surgerycaloric restrictionoverweightsRAGE

More Related Videos

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes05:08

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes

Published on: August 24, 2018

6.7K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

871

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
538
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
775
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
477
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.9K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
190